country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-N21831

Copy Link Print Information

Sarkomycin

Sarkomycin is a glutathione-targeting cytotoxic agent and antibacterial agent. Sarkomycin forms an addition product with glutathione, thereby reducing intracellular glutathione levels. Sarkomycin can induce cytoplasmic vacuolation, mitochondrial damage, cytoplasmic deformation, metaphase arrest, chromosomal abnormalities, nuclear degeneration, and nuclear fragmentation; it also modulates amino acid metabolism. Sarkomycin also inhibits anaerobic fermentation in affected cells in mice and inhibits cell growth in tissue culture, leading to the disappearance of mitotic cells, cell degeneration, and cell detachment from the glass surface. Sarkomycin can be used in research related to Yoshida ascites tumor, Ehrlich ascites tumor, Ehrlich carcinoma, and Yoshida rat sarcoma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 489-21-4
分子式: C₇H₈O₃
分子量:140.14

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Sarkomycin 構造式

CAS 番号: 489-21-4

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Carbohydrate MetabolismAnti-cancer

Carbohydrate Metabolism

Anti-cancer

Active forms of Sarkomycin (1000, 200, 100 mcg/mL; 80 minutes) strongly inhibit anaerobic glucose fermentation in Ehrlich ascites carcinoma cells, with 80-90% inhibition at 1000 mcg/mL, 20-40% inhibition at 200 mcg/mL, and 0% inhibition at 100 mcg/mL for Sy and SI^[2].

Anti-cancer

Sarkomycin exhibits equal activity against Ehrlich carcinoma cells as sarkomycin-INH, with Ehrlich carcinoma cells being 10-20 times more sensitive to sarkomycin than Yoshida rat sarcoma cells, while Yoshida rat sarcoma cells are approximately 2.5 times more sensitive to sarkomycin-INH than to sarkomycin^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Anti-cancerCell Cycle RegulationProtein/Amino Acid Metabolism

Anti-cancer

Cell Cycle Regulation

Protein/Amino Acid Metabolism

Sarkomycin (50 mg; i.p.; single dose) induces rapid, progressive cytological damage and marked elevations in free glutamine levels in Yoshida ascites tumor cells and fluid in WP rats^[1].
Sarkomycin (3.5 mg; i.p.; single dose) induces rapid, progressive cytological damage and marked alterations in free amino acid levels, including de novo glutamine appearance, in Ehrlich ascites tumor cells and fluid in A/He mice^[1].
Sarkomycin (3.5 mg; i.p.; single dose) induces identical rapid cytological and amino acid alterations in Ehrlich ascites tumor cells and fluid in C57BL mice as observed in A/He mice^[1].

Protein/Amino Acid Metabolism

Sarkomycin (30 mg/100 gm; i.p.; single dose) does not impair the ability of Yoshida ascites tumor cells to take up and convert exogenous glutamine, while altering specific cellular amino acid levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Pacific Farms Wistar (WP) (175 gm, Yoshida ascites tumor transplanted intraperitoneally 5 days prior)^[1]
Dosage:

50 mg
Administration:

i.p.; single dose
Result:

Reduced mitotic figures such that no normal mitotic figures were present by 120 minutes.
Induced cytoplasmic blebbing, chromosomal clumping, and scattering in metaphase cells by 30 minutes.
Caused severe cytoplasmic distortion, mitotic arrest at metaphase, and nuclear abnormalities by 60 minutes.
Resulted in over 50% of cells showing pyknotic chromatin aggregates by 120 minutes.
Greatly elevated cellular glutamine levels and induced glutamine appearance in ascitic fluid by 30 minutes, with further increases by 300 minutes.
Triggered progressive mitochondrial degeneration and marked intraperitoneal cellular reaction by 300 minutes.

Animal Model:

Pacific Farms Wistar (WP) (Yoshida ascites tumor transplanted intraperitoneally 5 days prior)^[1]
Dosage:

30 mg/100 gm
Administration:

i.p.; single dose
Result:

Preserved tumor cells' ability to take up labeled glutamine and convert it to glutamic acid.
Caused slight decreases in aspartic acid and glutathione levels in cells.
Induced appearance of a new unidentified ninhydrin-reactive substance in cells.

Animal Model:

A/He (35 gm average weight, Ehrlich ascites tumor transplanted intraperitoneally 48 hours prior)^[1]
Dosage:

3.5 mg
Administration:

i.p.; single dose
Result:

Induced cytoplasmic blisters, clumped/sticky chromosomes in metaphase cells, and chromonema-like structures in resting nuclei by 5 minutes.
Caused severe cytoplasmic blebbing and peaked abnormal nuclear structures by 10 minutes.
Triggered abnormal nucleus coalescence and degeneration, and elevated taurine levels in ascitic fluid by 20 minutes.
Resulted in extensive cytoplasmic damage and karyorrhexis, and marked elevations in cellular glutamine, valine, leucine, tyrosine, and lysine levels, plus elevated ascitic fluid glutamine, aspartic acid, taurine, and valine levels with decreased alanine and glycine levels by 40 minutes.
Eliminated all damaged cells, leaving a small number of normal-appearing tumor cells between 60 and 120 minutes.
Induced de novo glutamine appearance in cells, decreased glutathione levels, increased valine and leucine levels, and a new unidentified ninhydrin-reactive substance by 5 minutes.

Animal Model:

C57BL (Ehrlich ascites tumor transplanted intraperitoneally 3 days prior)^[1]
Dosage:

3.5 mg
Administration:

i.p.; single dose
Result:

Induced cytoplasmic damage and nuclear abnormalities.
Triggered appearance of glutamine in cells, decreased glutathione levels, increased valine and leucine levels, and presence of an unidentified ninhydrin-reactive substance.

Related Protocols :

化学情報

CAS 番号 489-21-4
分子量 140.14
分子式 C₇H₈O₃
SMILES

OC([C@H]1C(C(CC1)=O)=C)=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Microorganism
Streptomyces erythrochromogenes
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Roberts E, et al. Free amino acids in growing and regressing ascites cell tumors: host resistance and chemical agents[J]. Cancer research, 1956, 16(10_Part_1): 970-978.

[2]. Hara T, et al. Studies on Sarkomycin. VII Effects of Sarkomycin and Related Compounds on the Anaerobic Fermentation of Ehrlich Ascites Carcinoma Cells of Mice[J]. The Journal of Antibiotics, Series A, 1956, 9(5): 191-192.

[3]. Takeuchi T, et al. On antitumor effect of sarkomycin-INH[J]. The Journal of Antibiotics, Series A, 1958, 11(5): 212-216.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Sarkomycin

生物活性

製品説明

体外実験

体内実験

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Sarkomycin 関連分類

HY-N21831 関連分類

Bioz

Keywords

最近チェックした製品